The shortage-era explanation is out of date
Many older comparison pages explained compounded semaglutide and tirzepatide as routine alternatives during national shortages. That context has changed. FDA’s April 1, 2026 update says these ingredients are not on its drug shortage list or the 503B bulks list. An old shortage reference is not a current basis for mass-producing copies.
The FDA page also distinguishes earlier wind-down periods from its current reminder about legal conditions. A date from 2025 should not be presented as a future deadline in a 2026 article. Local difficulty finding a particular supply does not, by itself, establish a national shortage determination.
This does not support a blanket statement that every individual compounded prescription is lawful or unlawful. Compounding depends on the applicable statutory pathway and the facts of the prescription. For a patient, the useful next step is to ask why an approved medicine cannot meet the medical need and how the proposed preparation addresses it.
Sources: FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize | FDA
503A and 503B are different pathways
FDA’s current explanation says section 503A concerns compounding for an individual patient with a prescription and restricts regular or inordinate preparation of essentially copies of commercially available drugs. A documented prescriber determination of a significant difference for an identified patient can matter.
Section 503B outsourcing facilities have different conditions, including restrictions on using bulk drug substances. FDA’s April update specifically says semaglutide and tirzepatide are absent from the 503B bulks list and drug shortage list. A provider referring to a pharmacy’s registration is not a complete explanation of how a particular prescription meets the applicable conditions.
“Personalized” in advertising and the addition of a vitamin do not automatically settle the question. FDA discusses circumstances in which a semaglutide and vitamin B12 combination can still be essentially a copy. Ask for a clinical explanation rather than infer an exemption from a marketing label.
Sources: FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize | FDA
Approval and ingredient evidence are separate
FDA does not review compounded drugs for safety, effectiveness or quality before marketing. Its current consumer guidance recommends compounded products only for patients whose medical needs cannot be met by an approved medicine. Compounded medicine is not an FDA-approved generic version of Wegovy or Zepbound.
A trial of approved injectable semaglutide does not establish the performance of a compounded dissolvable tablet. A tirzepatide injection trial does not establish oral tirzepatide effectiveness. The active ingredient’s name does not remove differences in route, formulation, absorption, concentration, stability or product quality.
FDA also warns about semaglutide sodium and acetate, which are different active ingredients from those used in approved products. Its page says it is not aware of a lawful basis for using these salt forms in compounding. Ask the dispensing pharmacy exactly what is in the prescription rather than rely on a broad ingredient label.
Sources: FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss | FDA
Practical problems deserve specific instructions
FDA reports dosing errors involving compounded semaglutide, including patients measuring the wrong amount and clinicians miscalculating doses. Milligrams, milliliters and syringe units are different measurements. A dose chart from a previous vial cannot safely be reused if the concentration or syringe changes.
Ask the pharmacist to explain the labeled concentration, prescribed dose and the exact syringe marking before you inject. If those instructions do not match, do not improvise. Dose escalation should follow the clinician’s plan rather than a seller’s suggestion to increase faster.
FDA advises against using injectable GLP-1 medication that arrives warm or inadequately refrigerated. Its current multidose-vial guidance recommends discarding the vial within 28 days after first use even when compounder instructions suggest a longer period. Ask the pharmacy how that guidance applies to the supplied vial and planned number of doses, and use a new sterile needle and syringe each time.
Sources: FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss | FDA
Investigational peptides are not ordinary substitutes
The current FDA concerns page says retatrutide and cagrilintide cannot be used in compounding under federal law and are not components of approved medicines. Products marketed as research chemicals or “not for human consumption” should not be treated as a prescribing pathway.
A promising study headline does not establish approval or verify a product sold online. Research participants receive defined study materials under a protocol; a consumer bottle or powder with a similar ingredient name is a different source of risk.
Compare approved treatment, clinical access and the complete cost before assuming a deeply discounted unapproved product is the only option. If your clinician identifies a specific need for a compounded medicine, request the prescription, rationale, pharmacy identity, instructions and follow-up plan in a form you can review.
Sources: FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss | FDA